Skip to Main Content

Paper Details

A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
Journal of Clinical Investigation
112
2020
CD8, CD8+, CD8+ T cell, MDSC, NLRP3, NOD-, LRR-, and pyrin domain-containing protein 3, PD-1, PD-L1, PMN, PMN-MDSCs, anti-PD-1 antibody, cancer, granulocytic myeloid-derived suppressor cells, programmed cell death 1, programmed death ligand 1, tumor
Author NameAffiliation
Justin M BalkoVanderbilt University Medical Center
  • 1 - 1

Datasets

Release 1.2